VEGFA and breast cancer: Motesanib is a small molecule tyrosine kinase inhibitor of VEGF that targets VEGFR 1, 2, 3 and PDGF that has been evaluated in preclinical models in combination with either tamoxifen or docetaxel and was shown to have potential use in breast cancer.[68] A large phase II clinical trial is ongoing evaluating motesanib and paclitaxel in the treatment of breast cancer).[47]